In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTIHISTAMINE TUMOR-PROMOTION EPIDEMIOLOGY STUDIES UNDER CONSIDERATION

This article was originally published in The Tan Sheet

Executive Summary

ANTIHISTAMINE TUMOR-PROMOTION EPIDEMIOLOGY STUDIES UNDER CONSIDERATION by FDA in response to a study published in the May 18 Journal of the National Cancer Institute that found that three prescription antihistamines -- Schering-Plough's Claritin (loratadine), Janssen's Hismanal (astemizole) and Pfizer's Atarax (hydroxyzine) -- stimulate the growth of tumors in mice. In a May 17 "Talk Paper," FDA said it "is evaluating the feasibility of epidemiologic studies in patients with cancer."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel